Docket No.

285616US0PCT

IN THE UNITED STATES PATENT.	AND TRADEMARK OFFICE 13 MAR	
	ENCUNES WILLIAM 13 MAR	2006

IN RE APPLICATION OF:

Thomas RUECKLE, et al.

SERIAL NO:

New U.S. PCT Application Based on PCT/EP04/52143

GAU:

FILED:

Herewith

EXAMINER:

FOR:

SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

TOT	A TED CACEC
	A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).
	references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
M	The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be
related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies
of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the
attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Richard L. Treanor

Registration No. 36,379

Corwin P. Umbach, Ph.D. Registration No. 40,211

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

APPLICANT Thomas RUECKLE, et al. FILING DATE Herewith SROUP	Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 285616US0PCT		SERIAL NO.				
UIST OF REFERENCES CITED BY APPLICANT Thomas RUECKLE, et al. FILING DATE Herewith FILING DATE Herewith SROUP					Based on PCT/EP04/52143					
FILING DATE Herewith Herewith	LIST OF REFERENCES CITED BY APPLICANT									
Herewith U.S. PATENT DOCUMENTS SUB FILING DATE NAME CLASS FAPPROPRIATE CLASS CLASS FAPPROPRIATE CLASS CLASS FAPPROPRIATE CLASS CLAS							CROUR			
U.S. PATENT DOCUMENTS										
EXAMINER NAME CLASS SUB FILING DATE NAME CLASS SUB FAPROPRIATE							L			
INITIAL	EVANINED		DOCUMENT	γ-	I BOOMENTO		CUD		THE PATE	
AB 4 927 831 05/22/90 MALAMAS, Michael S. AC AD AB AF AF AG AF AG AH AI		INITIAL NUMBER DATE								
AC		AA		01/01/02	SCHINDLER, Ursula et al.		/ 1			
AD AE AF AG AH AI AI DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AJ 1088 815 04/04/01 EP NO AK 1088 821 04/04/01 EP NO AK 1193 267 AV 193 267 AV 193 268 AV 193 268 AV 193 269 AN 01/23378 04/05/01 WO AN 01/23378 04/05/01 WO AN 01/23378 04/05/01 WO AO 02/28856 04/11/02 WO AO 02/28856 04/11/02 WO AO 02/20856 AR RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select Genzoylaminomethyl-hiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. AN MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. AV Weltabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993. AV MERDOUIN, J.C: "Fifty years of hypoglycaemic Septinesimalides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.	,	AB	4 927 831	05/22/90	MALAMAS, Michael S.					
- AE		AC								
AF		AD								
AG	3	AE								
AH		AF								
DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO		AG								
DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO		АН								
DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO		Al		Ì						
NUMBER				FO	REIGN PATENT DOCUMENTS	·	•			
AJ			DOCUMENT	DATE	COLINTRY			TRANS	SLATION	
AK 1 088 821 04/04/01 EP NO AL 1 193 267 04/03/02 EP NO AM 1 193 268 04/03/02 EP NO AN 01/23378 04/05/01 WO NO AO 02/28856 04/11/02 WO NO AP 02/26733 04/04/02 WO NO AQ 02/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK),", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "INK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl)Phenyl"sulfonyl)-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.			NUMBER	DAIL	COONTRY		YES	3	NO	
AL 1193 267 04/03/02 EP NO AM 1193 268 04/03/02 EP NO AN 01/23378 04/05/01 WO NO AO 02/28856 04/11/02 WO NO AP 02/26733 04/04/02 WO NO AQ 02/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon-L. et al., "NK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AJ	1 088 815	04/04/01	EP				NO	
AM 1 193 268 04/03/02 EP NO AN 01/23378 04/05/01 WO NO AO 02/28856 04/11/02 WO NO AP 02/26733 04/04/02 WO NO AQ 02/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AK	1 088 821	04/04/01	EP				NO	
AN 01/23378 04/05/01 WO NO AO 02/28856 04/11/02 WO NO AP 02/26733 04/04/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK),", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AL	1 193 267	04/03/02	EP .				NO	
AO 02/28856 04/11/02 WO NO AP 02/26733 04/04/02 WO NO OZ/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon. L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AM	1 193 268	04/03/02	EP				NO	
AP 02/26733 04/04/02 WO NO OZ/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AN	01/23378	04/05/01	wo				NO	
AQ 02/100396 12/19/02 WO NO OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AO	02/28856	04/11/02	wo	******			NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AP	02/26733	04/04/02	wo				NO	
RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AQ	02/100396	12/19/02	wo				NO	
RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and select (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.			OTHER RI	EFERENCES (Including Author, Title, Date, Pertin	nent Pages, e	tc.)			
AR (Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003. BENNETT, Brydon.L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.								vel not	ent and selective	
AS Pages 420 to 425, 2003. MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discover Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AR	(Benzoylaminomethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers							
AT Vol. 2, No. 7, Pages 554-565, 2003. SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylan ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		AS	BENNETT, Brydon L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. 4,							
AU ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983. AV HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Française D'Endocrinologie Clinique-Nutrition E Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discovery, Vol. 2, No. 7, Pages 554-565, 2003.								
Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.		SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylamino ethyl]Phenyl"sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983.								
DEAVEN Corold M. et al. "Negligation Disheton Malliture Insulin Deficiency of Insulin Decistance? The American Journ								e-Nutrition ET		
AW Medicine, Vol. 60, Pages 80 - 88, 1976.	merican Journal of									
AX STOUT, Robert W., "Overview of the Association Between Insulin and Atherosclerosis", Metabolism, Vo. 34, No. 12, F	STOUT, Robert W., "Overview of the Association Between Insulin and Atherosclerosis",						, Metabolism, Vo. 34, No. 12, Pages			
AY DIAMANTI-kANDARAKIS et al., "Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycovary syndrome", Society of the European Journal of Endocrinology, Vol. 138, Pages 269 - 274, 1998.		enism in polycystic								
DUNAIF, Andrea, "Insulin Resistance and the Polycystic Ovary Syndrome: AZ Mechanism and Implications for Pathogenesis", Endocrine Reviews, Vol. 18, No. 6, Pages 774 - 800, 1997. Additional References sheet(s) atta		sheet(s) attached								
Examiner Date Considered	Examiner		<u> </u>			Date Co	nsidered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	*Examiner: In	itial if r	eference is considered,	whether or no	t citation is in conformance with MPEF	 P 609; Draw li		citation	if not in	

10/571466

New U.S. PCT Application Based on PCT/EP04/52143

AP20 Roc'd FCT/FT0 13 MAR 2006 Docket No. 285616 US

STATEMENT OF RELEVANCY

- 1) References AA, AJ AM & AR AV have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AB, AN AQ & AW -AZ are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.